Plans for IPOs and venture funding dominated the New England deals news this week.

—A new seed fund, backed by venture firm New Enterprise Associates and hosted by Harvard, came out of the woodwork last week. The Experiment Fund will invest up to $250,000 in seed funding in selected startups, with a focus on technologies that come out of Cambridge, MA. The news broke just a few days ahead of Facebook—the one that got away—revealing its plans to go public.

—Radius Health, a Cambridge-based startup working on treatments for osteoporosis, filed paperwork indicating its plans to raise as much as $86 million in an initial public offering.

—A PricewaterhouseCoopers and National Venture Capital Association report shows a mixed picture for life sciences investing in 2011, my colleague Arlene reported. Biotech companies raised $4.7 billion, showing a 22 percent increase over 2010, but the deal volume for the sector dropped 9 percent to 446 transactions. Medical devices companies also showed an increase in funding dollars but a drop in number of deals.

—Cambridge-based Brightcove set the price range of its initial public offering at $10 to $12 per share, according to an amended filing with the SEC. The video hosting startup plans to sell 5 million shares, and give underwriters the option to purchase another 750,000 shares. Brightcove first filed paperwork last August indicating it intended to raise $50 million in an IPO.

—Synchroneuron of Waltham, MA, nabbed $6 million in Series A funding from Morningside Technology Ventures. The startup is developing treatments for movement disorders such as tardive dyskinesia.

Comments | Reprints | Share:          

Applied Proteomics hasn’t exactly been operating in stealth mode since it was founded five years ago. Co-founders David Agus, a cancer specialist at USC, and Danny Hillis, the MIT-trained computer scientist, gave TedMed talks about the startup’s technology, which provides a 40-gigabyte snapshot of all the proteins circulating in a drop of blood. By pure coincidence, I watched John Stewart’s Feb. 2 interview with Agus last night on “The Daily Show.”

“Danny and David had the foresight to build the tool before trying to use the tool,” says John Blume, a molecular biologist who joined API in 2008 as chief scientific officer. “Although the company wasn’t in stealth mode, the first several years were spent in taking the time to make it right, and then to use it and avoid some of the stumbling blocks.”

Now Applied Proteomics is raising the curtain on several steps that mark its progress beyond a seed-stage startup that was incubating at Applied Minds, an industrial think tank that Hillis founded in Glendale, CA, with a colleague from Disney Imagineering. After moving the headquarters to San Diego late last year, Applied Proteomics is today naming a new CEO—Peter Klemm, a veteran in molecular diagnostics and the former CEO of Lexington, MA-based Predictive Biosciences.

Danny Hillis

The company known as API says it also secured $22.5 million last June in Series B funding from Domain Associates (San Diego partner Jim Blair joined the board), Seattle’s Vulcan Capital, and returning angel investors. Klemm tells me the company raised $4 million from angel investors (who prefer to go unnamed) in what amounted to API’s Series A round in 2007.

David Agus

API’s goal, Klemm says, is nothing less than to “elevate molecular diagnostics to another level beyond the genome” by measuring the proteins made by genes—a long-sought technology that is expected to help doctors improve medical care for individual patients. Because proteins carry out most cellular functions, the company says a snapshot of all the proteins circulating in the body at a given moment represents “the most powerful source of information” in terms of understanding a patient’s health status.

Quantifying all the proteins in the body, Klemm says, can help doctors optimize the course of treatment for individual patients by making it easier to identify the specific drugs that would have the greatest effect on blocking specific proteins or signaling pathways, which can vary dramatically from person to person.

In a statement from the company, Hillis says, “For the first time, we can look at all the proteins in the body with remarkable specificity and sensitivity and use proteomic technology to create … Next Page »

Comments | Reprints | Share:          

We’re starting to see fresh signs of life among the Internet software startups in San Diego. Check out this news.

—During a visit last week, TechStars CEO David Cohen talked with the leaders of San Diego’s grassroots Web startup community about the factors that help to create and sustain entrepreneurial communities. One crucial issue confronting San Diego is a crying need for savvy and experienced Internet entrepreneurs who are willing to “pay it forward” by mentoring a new generation of startups.

—A dozen seed-stage companies moved into the new EvoNexus incubator in downtown San Diego. EvoNexus, which was founded by the CommNexus non-profit industry group, will continue to operate its original incubator in University City, where eight startups are taking root. In both locations, EvoNexus provides office space, utilities, and other services free of charge and with no strings attached.

—Sigma Partners led a $10 million round in venture funding for San Diego-based MOGL, a Web startup that has developed a comprehensive customer loyalty program for restaurants and bars, to fuel its expansion into San Francisco and New York. San Diego’s Avalon Ventures and Austin, TX-based Austin Ventures joined in the round.

—San Diego’s MicroPower Technologies named two new board members after raising $6.5 million in Series C funding in a deal that was led by Motorola Solutions Venture Capital and joined by an undisclosed private fund. MicroPower Technologies, which uses wireless networking technologies to create low-cost surveillance capabilities, named PacketVideo CEO Jim Brailean and former DivX CEO Kevin Hell to its board. Hell, who is now chairman of San Diego’s EvoNexus incubator, will join as MicroPower chairman.

—San Diego’s StockTwits said it has established a partnership with Toronto’s Q4 Web Systems, which provides … Next Page »

Comments | Reprints | Share:          

Xconomy held its first Big Apple tech event (well, mostly tech, since there was one life sciences company on hand) on Wednesday. We called it New York’s Venture Emergence, and a fantastic crowd of nearly 250 turned out to the Apella Center on East 29th Street for an afternoon of startup snapshots, VC-entrepreneur stories about building great companies, and keynote chats featuring some of New York’s hottest emerging companies and investors.

On the VC side, speakers included Fred Wilson of Union Square Ventures, RRE Ventures’ Eric Wiesen, Nick Beim of Matrix Partners, Todd Dagres from Spark Capital, Rich Levandov of Avalon Ventures, Michael Greeley from Flybridge Capital Partners, and Dennis Purcell of Aisling Capital.

Companies presenting included bitly, Gilt Groupe, Armgo Pharma, Simulmedia, BarkBox, and Gotham Greens. We also heard from HackNY and Barry Silbert, founder and CEO of SecondMarket—on the day Facebook filed to go public.

We snapped a lot of pictures of the speakers—and our audience. Following is a selection of shots of both. We hope you enjoy them.

A great thanks to our venue host, Alexandria Real Estate Equities, and our fantastic event sponsors: Cooley, EisnerAmper, Halloran, IDA Ireland, and TriNet. Special thanks as well to the National Venture Capital Association and New York Angels, which went above and beyond to help with this event.

And thanks most of all to all of you who came to see it, and made such a great crowd. I hope we got a picture of you.

(Xconomy digital media intern Teddy Worcester contributed to the production of this slideshow)

	NEXT IMAGE >>
	New York’s Venture Emergence — The crowd gathers
	Photo by Keith Spiro Photography courtesy of Kendall Press

… Next Page »

Comments | Reprints | Share:          

When it comes to tech startups—especially in Internet software and app development—San Diego has been adrift in the horse latitudes. That’s the term Spanish mariners had for the waters where the trade winds died out for days and even weeks at a time. Becalmed sailors desperate to gain some headway would heave their horses overboard to reach the New World.

It hasn’t reached that point yet in San Diego, but you would never know that software was once a thriving entrepreneurial community here. Even now, the software sector accounts for more than a third of San Diego’s private technology companies. But as I’ve written previously, it feels as if the local software companies speak different languages. In contrast to the flourishing tech hubs in Seattle, Boston, and New York—not to mention Silicon Valley—San Diego’s software scene is sleepy and indifferent.

Still, there are signs of a freshening breeze.

David Cohen last week at UC San Diego

Scores of new seed-stage startups have begun to emerge throughout the region, including a dozen that just moved into the new EvoNexus incubator in downtown San Diego. These emerging companies are led by young entrepreneurs who view San Diego’s innovation establishment as old-school and irrelevant. They are turning out instead for informal “hackathons” and “meetups.” They tell me they’re yearning for real mentoring by real tech entrepreneurs, and for access to real tech investors who are really investing.

Last week, more than 200 people turned out to hear David Cohen talk at U.C. San Diego about TechStars, the early stage fund and accelerator program for Internet startups that he co-founded with three partners in Boulder, CO, six years ago. Cohen is the CEO, and by any measure, the startup program has been wildly successful.

TechStars enrolled its first 10 Internet startups in 2007, providing as much as $18,000 in seed funding and an intense, three-month mentorship program for each company in exchange for a 6 percent stake. Since then, TechStars has expanded to … Next Page »

Comments (9) | Reprints | Share:          

Don’t know about you, but I’m less interested in Facebook’s IPO than I am in the efforts of people trying to find the next Facebook out of Boston/Cambridge. One such effort is the new Experiment Fund, based at Harvard University, which I wrote about earlier this week.

Turns out there’s more to the latest seed-stage fund in Boston than initially meets the eye. I had a chance to speak with the Experiment Fund’s co-founders, Hugo Van Vuuren of Harvard and Patrick Chung, a partner at Silicon Valley-based New Enterprise Associates (not that Patrick Chung, that Patrick Chung).

They clarified the goals of the new fund and provided some more context around how it plans to distinguish itself from other similar efforts. I’ve also talked with a number of other early-stage investors around town and have gotten a better sense of how the Experiment Fund is being received locally (more on that below).

First, some mechanics of the fund, which has been in the works for about two years. Harvard has no financial stake and will have no say in the fund’s investment decisions, but it has provided support and office space, Van Vuuren says. He declined to specify the projected size of the fund, but he said it plans to make four to six new investments over the next two years, each in roughly the $100,000 to $250,000 range.

The Experiment Fund has already invested in four companies: Rock Health (see my colleague Wade’s stories here and here), Omada Health, Punch Media, and Tivli. Interestingly, only Tivli is based in the Boston area. Rock Health and Omada are in San Francisco, and Punch Media is in the DC area. They all were started by Harvard students—the key ingredient for now—but the fund intends to invest in teams from other schools around Boston and the East Coast, as well. So I’m guessing its next four investments will be pretty different from its first four, at least geographically.

“We want to meet them here,” Chung says. “We want to help you right here in Boston where the ideas were first born, where the team was put together.”

One issue they wanted to address was the notion that the fund is … Next Page »

Comments | Reprints | Share:          

The Northwest chapter of angel investment group Keiretsu Forum says its members invested $24 million in 36 companies last year, the highest total since the regional group was formed in 2005. And most of those investments—29 of the 36—were for businesses in the region, Keiretsu says. Nine of the investments were follow-on rounds, and 27 were new deals.

That’s a significant uptick from 2010, when Keiretsu reported just $8.9 million invested in 16 companies, an amount that was still billed at the time as “encouraging,” considering the ongoing economic turmoil. While the economy at large still hasn’t rebounded, technology ventures and angel investors are clearly seeing some optimistic signs.

One thing that stood out to me in perusing the statistics from Keiretsu was that a sizable chunk of these investments went to other investment funds, not startup companies—about half the money went into either real estate funds (38 percent, roughly $9 million) or alternative investment funds (11 percent, about $2.6 million). The rest broke down this way: Technology companies, 30 percent; consumer/retail, 16 percent; life sciences, 4 percent.

Keiretsu Forum Northwest—which encompasses the greater Seattle area along with Portland, OR and Boise, ID—has accounted for nearly $90 million in funding for about 150 companies since the regional chapter was founded in fall 2005. Chapter president Nathan McDonalds says 78 new members were added in the region during the last year.

Some of the Washington-based companies financed through Keiretsu included Atossa Genetics, Cadence Biomedical, NanoICE, and Valant Medical Solutions.

Comments | Reprints | Share:          

This week’s deal news covered a breadth of sectors: biotech, medical devices, mobile applications, software, and robotics. Not to mention a major venture capital fund raise.

—Waltham, MA-based drugmaker Avila Therapeutics was bought by New Jersey-based Celgene (NASDAQ: CELG) for $350 million, with as much as another $575 million available in milestones. Avila is a maker of “covalent” drugs that are designed to shut down the activity of disease-causing proteins for a prolonged period of time.

—Verastem, a young Cambridge, MA-based biotech working on drugs targeting cancer stem cells, completed its initial public offering, led by UBS and Leerink Swann. The IPO (5.5 million shares sold at $10 apiece) represented a strong showing among investors, as Verastem originally indicated it planned to sell 4.5 million shares priced between $9 and $11 each. The underwriters have a 30-day option to buy another 825,000 shares.

—Burlington, MA-based ConforMIS, a maker of knee implant systems, raised $89 million in a Series E funding from private equity investors and government investment funds abroad. The company said it will put the money toward sales, manufacturing, and expansion of its technology.

—Co3 Systems, a maker of data loss management software, received new funding from Fairhaven Capital. The Cambridge, MA-based startup said it will put the money (whose sum was undisclosed) toward sales, marketing, and engineering.

—Malborough, MA-based medical device startup Navilyst Medical will be acquired by Albany, NY-based AngioDynamics (NASDAQ: ANGO) in a transaction valued at $372 million, based on the company’s $14.20 per share closing stock price Monday. Navilyst, which focuses on … Next Page »

Comments | Reprints | Share:          

There’s a new player in the seed-stage investment game in Boston. As of this week, the Experiment Fund is open for business at Harvard University, backed by the Silicon Valley venture firm New Enterprise Associates (NEA). The startup investment fund is being hosted by Harvard’s School of Engineering and Applied Sciences in Cambridge, MA.

The new fund is led by Hugo Van Vuuren (see photo above), a Harvard graduate student and entrepreneur, and two venture capitalists from NEA, Patrick Chung and Harry Weller (both Harvard alums). David Edwards, a Harvard professor of biomedical engineering, serves as an advisor to the fund. Van Vuuren and NEA did not respond to requests for comment in time for this article.

The basic structure of the Experiment Fund is that selected startups—mostly student-led teams from Cambridge—will receive up to $250,000 in seed funding over the next two years, presumably in exchange for a sizable equity stake in the companies. The fund is based out of Harvard but says it will operate independently of the university and will look at teams from other local schools—and, more broadly, from the East Coast. The sectors targeted are pretty broad as well; they include information technology, healthcare, and energy.

No word yet on the size of the fund or how many companies it will invest in. But Van Vuuren, a recent fellow at Harvard’s Berkman Center for Internet and Society, said in a press release that he and his partners are looking for “smart and resourceful people, zealous full-time teams, and experiments in need of seed funding and hands-on help to get off the ground.”

Not to beat a dead Zuckerberg, but the overarching goal here is to keep the next Facebook in Boston—and, preferably, affiliated with Harvard. “It’s continued growth of the ecosystem for Harvard and beyond,” says Gordon Jones, director of the Harvard Innovation Lab, which is collaborating with the Experiment Fund to provide office space and resources, but is separate from the new fund. Jones calls the Experiment Fund “extremely complementary” to the i-Lab.

One of the first Harvard teams to receive an investment from … Next Page »

Comments | Reprints | Share:          

San Diego’s StockTwits is developing a bit of a Canadian accent, eh, through a partnership being announced today with Toronto-based Q4 Web Systems, which provides online investor relations services for publicly traded companies throughout North America.

StockTwits is an online social media network that enables traders and shareholders to share their market insights, ideas, charts, and news in real time via Twitter. The startup structures financial and investor-related information from its Twitter feed by stock, user, reputation, and other criteria. StockTwits also enables users to save the stocks they follow to their own portfolios and to limit the comments tweeted about each stock to trusted sources.

As I reported last summer, the four-year-old startup has determined that its chief source of revenue also lies with the investor relations and public relations units of publicly traded companies.

By introducing a ticker tag symbol for publicly traded stocks, $(ticker), StockTwits makes it possible for public companies to sign up for a higher level of StockTwits’ Web service and to “claim” their stock tickers. Once claimed, a company’s IR and PR teams can use the ticker tag to distribute corporate information over the Web in real time.

By partnering with Q4, StockTwits plans to integrate its services with the subscription-based services that Q4 provides its corporate customers. Q4 says its website services include more than 30 IR “best practices” modules that help companies properly provide information and other services to investors and shareholders.

“We’re working with them to make it easier for people to use both of our products,” says Francis Costello, StockTwits’ chief operating officer. He tells me StockTwits has more … Next Page »

Comments | Reprints | Share:          

San Diego’s MOGL, a Web-based customer loyalty and rewards program for restaurants and bars, says it has raised $10 million in venture funding to fuel its expansion into San Francisco, New York, and other markets.

The Menlo Park, CA, office of Sigma Partners led the Series B round, which was joined by San Diego’s Avalon Ventures and Austin, TX-based Austin Ventures. That brings total funding for MOGL to $12.4 million, according to a statement from the company. Entrepreneurs Jon Carder, Jarrod Cuzens, and Jeff Federman started MOGL in 2010.

The Internet startup offers its customers multiple incentives for returning to member restaurants and bars, using a mixture of technology, games, and psychology. The incentives include a 10 percent cash back each time a customer returns to eat at participating restaurants. A contest  offers monthly cash prizes to the top three most-frequent customers at each locale. Customers also can automatically donate a meal to someone in need every time they spend $20.

MOGL Homepage Screenshot

MOGL says it provides customer analytics and return-on-investment data for participating bars and eateries. In a statement from the company, Sigma partner Peter Solvik says, “The MOGL team has generated an explosive response from both consumers and restaurant partners, while effectively positioning itself as the most innovative loyalty platform of its kind.”

Since it was launched last April, MOGL has signed up nearly 350 Southern California-based eateries and bars, donated more than 27,000 meals to Feeding America, and has rewarded its members with more than $350,000 in cash back to date.

The company also offers a location-based mobile app for iPhone and Android, so MOGL members can easily locate participating restaurants while on the go. The mobile apps also help customers track their cash rewards and jackpot opportunities, as well as the number of meals donated in their name.

Comments (1) | Reprints | Share:          

Serial entrepreneur Angel Gambino has every right to be arrogant—as people with resumes like hers often are—but she’s as down-to-earth and polite as they come.

Sure, a casual question about which local gym she prefers reveals that she’s currently training to be an Olympic soccer-team liaison, the Olympics’ most senior volunteer role and one which oversees every aspect of the team’s participation in the international games, but the answer is delivered in such a gradual, casual manner that it’s hardly bragging. (She’s awaiting confirmation from the Olympic Committee whether she’ll be overseeing the American, English, Italian, Australian, Brazilian, or Argentine men’s team.)

Trust me when I say Gambino’s life is way more interesting than mine and probably yours. She helped develop Gameplay.com, an early gaming site that eventually had 900 employees in nine countries; was instrumental in helping to popularize the social network Bebo, which was sold to AOL Time Warner in 2008 for $850 million; helped oversee the BBC’s expansion into mobile, broadband, and on-demand platforms; and helped launch social and video-on-demand platforms for Viacom channels such as MTV, VH1, and Comedy Central.

Gambino is still a co-owner of Sonico, the third largest social network in Latin America—Gambino describes it as “the Facebook of Latin America before Facebook became the Facebook of Latin America”—as well as Spoonfed Media, a popular website that directs Londoners to upcoming arts and entertainment events.

So what the heck is she doing in Detroit?

Gambino and her partner, Scott Griffin (more on his story later), purchased a massive building on Rosa Parks Blvd. for $270,000 in September, which they plan to turn into retail, restaurants, and space for local startups, the first step in a plan to further revitalize the Corktown area so it attracts not only the suburban visitors that are already coming in droves to eat at the neighboring Slow’s Bar-B-Q, but also to send the message to entrepreneurs around the globe that Detroit is the place to be.

“Detroit is a city of tremendous opportunity—I don’t know any other cities like it in the world,” Griffin says. Responding to the question of why two people as worldly as he and Gambino would choose Detroit as their base of operations, Griffin says, “I wonder why there aren’t more of us here already. I don’t understand why there aren’t a thousand of us here competing for these deals.”

Gambino was actually born in Detroit, though she spent her formative years in the suburbs outside of the city. Even in her youth, she says it was obvious to her that there were a lot of things lacking in Detroit.

“I knew Detroit was famous for sports and music, but not much else,” Gambino says. … Next Page »

Comments (2) | Reprints | Share:          

Last week Steve Case wrote an op-ed in the Washington Post called “Give Entrepreneurs Room and They Will Grow the Economy.” For those not familiar with him, Case was the founding CEO of AOL and has been an active healthcare investor, among other things, for the past seven years. My firm, Psilos Group, has co-invested in a health company with with Case’s Revolution Health Fund.

Anyway, it was a very good editorial and one of the statistics within it particularly stood out to me in light of my venture capital role: firms less than five years old have produced 40 million American jobs over the past three decades—accounting for basically all of the net new jobs created in that period. That is a pretty stunning fact and also one that really makes a person scratch their head about current U.S. policy towards startups.  It is worth watching this Kauffman Foundation 3 minute video that is very instructive about start-ups and job creation.

Nowhere is this issue more relevant than in the healthcare industry, which conveniently happens to be the only thing I know anything about. In a world where there is no way out of the healthcare crisis except through the generation of new ideas to solve our healthcare problems, young companies are the golden ticket to new employment.

In his State of the Union speech last week, President Obama specifically stated that he wanted Congress to work with him to institute policies that advance research in medical devices, a field in which the U.S. has long been the leader. However, due to a combination of factors, including several government policies, we are now in peril of losing this supremacy to other nations like China and India. Research is nice, but tax and other policies that support the genesis of new companies and growth of existing ones are better right now in a world where medical device start-ups can’t catch a break. As AdvaMed President Stephen Ubl points out, the Patient Protection and Affordable Care Act (PPACA) imposes a $20 billion annual tax on the medical device industry to help cover the cost of health reform, and this new tax is already causing layoffs at large and small companies. FYI, the companies that sell branded drugs will also be hit with a $2.5 billion excise tax. Add these taxes to the challenges and costs presented by today’s FDA and it’s a toxic cocktail.

The small start-up companies that have answers to our healthcare challenges should be growing, not shrinking, but they are gasping for air in the current environment. I was in a board meeting at a medical device company just last week where we had a frank discussion about the R&D projects we would have to forego in order to cover this medical device tax, which is being imposed equally on large profitable and young unprofitable companies starting in 2014.

If healthcare startups are not allowed to thrive, I can assure you that the jobs in healthcare are not going to come from larger healthcare entities, either. The American Hospital Association has stated that anticipated reductions in Medicaid and Medicare funding and reimbursement will cost hospitals 278,000 jobs as revenue declines in these programs. The pharmaceutical industry has already laid off over 124,000 people in the last three years; expected further consolidation in this field isn’t going to help. The large medical device companies have also been shedding their staffs. It is the young upstarts that make the jobs appear.

As Steve Case clearly says in his op-ed, “America’s best chance to achieve robust, sustainable growth and prosperity is by ensuring that the United States increases its entrepreneurial competitiveness relative to the rest of the world.” There has been some activity in the form of a variety of bills supporting crowdsourcing of young companies (although that is a mixed bag, if you ask me), relaxed Sarbanes-Oxley rules to encourage smaller companies to go public, the StartUp Act, and others. But so far these are bills, not laws, and startups are having a hard time raising financing, particularly in a world where the IPO market is so compromised. It is worth noting, for instance, that in the last four years there were a total of nine medical device IPOs but in the four preceding years there were an average of 13 per year. In the pharma/biotech sector, a similar phenomenon: 26 IPOs in the last four years in total and an average of 21 per year in the prior three years. This is important because IPOs have traditionally given these young firms the capital to grow exponentially, creating many jobs in their wake.

Case refers to a great Thomas Edison quote in his Op-Ed that applies perfectly to the entrepreneur: “Vision without execution is hallucination.” Nothing could be more true, as I have seen hundreds of entrepreneurs over the years I have been a healthcare investor, and it is only those who have the gene for excellent execution that reach nirvana. I can’t say if the others are merely hallucinating, but I have my suspicions.

Edison’s quote applies equally well to our lawmakers, however, who are all running around saying “Jobs! Jobs! Jobs!” when they are not busy pointing out which Republican candidate is the true pillar of family values. Job creation can be the byproduct of these lawmakers’ endeavors but … Next Page »

Comments (1) | Reprints | Share:          

“It is the ‘silver’ age of VC/entrepreneurship. It would be the ‘golden’ age if we could fix the liquidity issues.”

Those are the words of Michael Greeley, general partner of Flybridge Capital Partners in Boston and treasurer of the National Venture Capital Association, referring to the very tight IPO market that is limiting capital-raising options for emerging growth companies. It is also an issue Greeley intends to explore this Wednesday afternoon, at Xconomy’s conference: New York’s Venture Emergence.

That’s because Greeley will be the moderator of a keynote chat with Barry Silbert, CEO and founder of SecondMarket, the hot New York broker-dealer that is doing its share to fix the aforementioned liquidity issue, in large part by creating ways to trade shares of privately held companies.

The chat between Silbert and Greeley is just one part of a fantastic afternoon of discussion and stories from some of New York’s—and the country’s—leading venture capitalists and entrepreneurs, including Union Square Ventures’ Fred Wilson, the Gilt Groupe founding team, 1stdibs CEO David Rosenblatt, RRE Ventures’ Eric Wiesen, Internet advertising pioneer Dave Morgan (now CEO of startup Simulmedia), Todd Dagres of Spark Capital in Boston—and a whole lot more.

If you don’t have your tickets already, get them fast—time is running out, and space is limited.

Greeley says he is really looking forward to his chat. Some questions he intends to ask Silbert include:

—What is the future of stock exchanges, and how companies raise capital and generate shareholder liquidity?

—What does Second Market look like in five years?

—What are the greatest risks to the business going forward?

—What regulatory issues do companies like Second Market face, and what should the government do?

And last but not least, says Greeley (who remember is from Boston): Who will win the Super Bowl? (I personally feel it will be the Patriots’ revenge).

There will also be time for you to ask Silbert a few questions of your own. We look forward to seeing you on Wednesday afternoon. Register here.

Comments | Reprints | Share:          

In my recent piece Reengineering Capitalism I highlighted a phenomenon that the global entrepreneurship ecosystem is paying very little attention to: Over 99 percent of entrepreneurs who seek funding get rejected. Yet, the entire world is focused on the 1 percent that is “fundable.”

The media, when pitched a startup story, is interested in who funded the venture. They seldom ask how much revenue the company has or if it  is profitable.

Incubators take pride in how exclusive they are and how many “deals” they “reject.”

Angels and VCs, of course, discard most of their “deal flow.”

And entrepreneurs? They seem to have confused the definition of entrepreneurship altogether. Entrepreneurship, they mistakenly believe, equals financing!

This is wrong.

There are numerous stories of successful businesses that have been built without a penny of outside financing. I want to share with you some wisdom from the heroes of the other 99 percent. They live in a world of entrepreneurs who enjoy their freedom and are not looking to sell their businesses or take them public. You could say these businesses are built-to-enjoy, as opposed to built-to-flip. Needless to say, outside financing, by definition, requires an “exit,” and for most businesses, that means a sale to a larger company.

But the entrepreneurs I will introduce you to today are not interested in selling their companies. They just want to continue doing what they are doing: building value.

Meet Girish Navani, CEO of eClinicalWorks, a super-successful healthcare IT company based in Boston. He has never taken any funding but has built a $100 million-plus business by delivering value to customers.

Girish says, “I don’t foresee leaving the company for at least 10 years. I would like to leave it a private company with no external investors and absolutely no thoughts whatsoever about Wall Street. I am having fun and take great pride in my freedom. There is no reason I would give that up. We are a cash flow positive company. We have recurring revenues and no debt. We have a large customer base that is growing exponentially.” (You can read Girish’s full story here.)

Meet Andrew Fox, CEO of ClubPlanet, a $30 million-plus nightclub ticketing services company that is also 100% founder-owned. Andrew loves nightlife and says, “The business is very successful and has a lot of room for growth. I think that we have a lot of suitors out there who mention really ridiculous numbers at times. This is such a great lifestyle business that I don’t know if I could ever sell it. All of my previous businesses I built to sell, but this time around you might find me right here in thirty years. I hope by then it is $300 million a year. Based on our growth trajectory, we are seeing really good signs of improvement. (You can read more of Andrew’s story here.)

Then there is the oft-cited Sridhar Vembu, who has turned all tables with Zoho, a $100 million-plus SaaS company that … Next Page »

Comments (4) | Reprints | Share:          

It’s that outlook time of year, and Mark Heesen, president of the National Venture Capital Association (NVCA), was in San Diego earlier this week, talking about the 2012 outlook for venture capital. Today he’ll make a similar presentation to the New Jersey Technology Council. Next week,  John Taylor, the NVCA’s director of research is set to talk in Florida about the 2012 outlook.

Heesen began his presentation in San Diego by saying, “Be prepared for a roller coaster ride here, because that’s where we’ve been for the past year—and that’s where we’re going.”

In a conversation with Xconomy yesterday, Heesen talked about some of the broader trends he’s charting throughout the United States. Here are some of the takeaways from our talk, and from Heesen’s presentation in San Diego:

—The VC industry continues to contract. Venture capital investments in U.S. startups peaked in 2000, when VCs sank $99 billion into emerging companies of all kinds. There were 1,022 venture capital firms at that time, and they were collectively managing $220 billion worth of invested capital. In 2010, VCs invested more than $20 billion into startups of all kinds. The number of VCs had plunged by almost 55 percent—to 462 VC firms with $177 million under management.

—VCs are raising more capital from their limited partners, but it isn’t enough to sustain current investment levels. In 2011, U.S. venture firms raised a total of $18 billion. That was up significantly from the $14 billion that VCs raised in 2010—but it falls $10 billion short of covering the $28 billion that VC firms invested in 2011. As a result, Heesen says he expects venture investments in U.S. technology and life sciences companies to decline in 2012.

—A handful of VC firms accounted for … Next Page »

Comments (1) | Reprints | Share:          

Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French.

The concept was unorthodox 25 years ago, yet over time, most every Big Pharma company has become an active equity investor in biotech startups. But Holtzman, early in his tenure as lead dealmaker at Weston, MA-based Biogen Idec (NASDAQ: BIIB), chose to buck the trend, helping put the kibosh on the company’s VC investment group in the past year. This was no small decision, given that Biogen started its venture investing group in 2004, committed $200 million to it, and made investments in companies like San Diego-based Intellikine, South San Francisco-based iPierian, San Diego-based Calcimedica, and Cambridge, MA-based Aveo Pharmaceuticals (NASDAQ: AVEO), among others.

Holtzman outlined four main reasons why Biogen has gotten out of the VC game during an interview earlier this month at the JP Morgan Healthcare Conference. But before diving into those reasons, they should be placed in the context of what’s been a busy first year of dealmaking he has overseen as part of CEO George Scangos‘s new management team at Biogen.

Besides shutting down the venture investment effort, Biogen also closed down its startup incubator, so that more resources could go to internal R&D projects, Holtzman says. Given that Biogen has plenty of drug candidates (six) in the third and final phase of clinical trials usually required for FDA approval, Holtzman’s mandate has been to in-license drugs that can fill gaps in the early-stage part of the pipeline. Two recent partnerships, with South San Francisco-based Portola Pharmaceuticals and Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS), reflect that desire. Expect more in-licensing of early-stage drug candidates for autoimmune and neurological disorders in the year to come, Holtzman says.

Given that backdrop, here are the four arguments that Holtzman says are commonly made in favor of corporate VC activity, which he says don’t make sense for Biogen:

1. “Corporate VC investing provides a window on novel technologies.” That might sound reasonable on the surface, but Holtzman says it’s not necessary, and not the best way to stay plugged in. “I’d submit to you that the best window on novel technologies comes from your scientists, who are identifying new things all the time,” Holtzman says.

2. “It’s a good way to network with VCs who have an inside look at what’s hot. If you don’t invest with them, you aren’t connected to them.” This argument doesn’t apply to Biogen, because its senior executives—particularly Scangos, R&D head Doug Williams, and Holtzman—have all been in the biotech business for 25 years and have extensive Rolodexes in the venture capital world.

“We are intimately familiar with all the VC players on a first-name, friendly basis,” Holtzman says. “We have multiple meetings here [at the JP Morgan conference] with the leading VCs in the industry, where they sit down and go through every company in their portfolio that might be of interest to us. We are very happy to do that. We get calls regularly from VCs who say, ‘We’re thinking of starting a company in the following area. Are you interested in that area?’ And beyond that, they ask us, ‘What do you think are the interesting areas where we ought to start companies?’

Personal relationships with the VCs can be forged … Next Page »

Comments (1) | Reprints | Share:          

Cambridge, MA-based Verastem, the biotech startup seeking to make drugs against cancer stem cells, found a way to rustle up enough demand from investors to complete its initial public offering.

The company (NASDAQ: VSTM) said tonight that it raised $55 million by selling 5.5 million new shares at $10 apiece. It was a strong showing of investor interest, given that Verastem had previously proposed selling just 4.5 million shares, at a range of $9 to $11 a share. UBS and Leerink Swann led the offering, and were assisted by Lazard Capital Markets, Oppenheimer & Co., and Rodman & Renshaw, according to a statement on Verastem’s website. The offering could end up raising more money in the end, because the underwriters have a 30-day option to buy another 825,000 shares. Shares of Verastem will now start trading on the NASDAQ on Friday, the company said in a statement.

The IPO was a bold move in a market that has shown limited interest in such offerings from biotech startups, especially companies like Verastem, which was founded in August 2010 and doesn’t yet have any drug candidates in clinical trials. While Verastem contends that cancer stem cells—also known as tumor-initiating cells—are critical players that help tumors resist treatment and spread, scientists still have a lot to prove about the role they play. The bet here is essentially on an intriguing field of science and a high-profile cast of scientific advisors and executives led by CEO Christoph Westphal. He’s best known as the former CEO of Sirtris Pharmaceuticals, the developer of drugs for diseases of aging, which was sold to GlaxoSmithKline for $720 million in 2008.

Christoph Westphal is chairman and CEO of Verastem

Investors haven’t shown much interest in backing such high-risk/high-reward companies like Sirtris or Verastem lately. Last year, just 10 biotech companies went public, according to a tally from FierceBiotech, down from 13 a year before. At least a couple of other notable biotech companies are teed up to test the IPO market in the early days of 2012—Mountain View, CA-based ChemoCentryx, which is trying to sell 4 million shares at $14 to $16 a share, and Cambridge, MA-based Merrimack Pharmaceuticals, which is attempting to sell 16.7 million shares at $8 to $10 apiece, according to the most recent regulatory filings.

The Verastem offering stands to benefit a number of well-known players in the Boston biotech community. Heading into this deal, the biggest holders in Verastem were Longwood Founders Fund, with a 15.4 percent stake; CHP of Princeton, NJ with 13.5 percent; MPM Bioventures with 13.1 percent; Bessemer Venture Partners with 12.9 percent; Eastern Capital Limited with 7.8 percent; and Advanced Technology Ventures with 5 percent.

Comments (1) | Reprints | Share:          

Avila Therapeutics, after just five years in business and $51 million in venture capital, made big news today when it agreed to be acquired by Celgene for $350 million upfront plus another $575 million in milestone payments.

Naturally, there are a lot of people celebrating the success of the Bedford, MA-based company today around the web and on Twitter.

Over at Polaris Venture Partners’ blog, Amir Nashat wrote that “early, Series A life sciences investing pays off.”  He added that this portfolio company is the eighth in the last three years to generate returns, either through acquisition or an IPO. “One common thread that binds each of these companies was their compelling scientific foundation and transformative potential for treating disease. In our model, these areas are essential and go hand-in-hand with strong teams. In the case of Avila, we were fortunate to back a truly unique team of repeat entrepreneurs,” Nashat wrote.

Bruce Booth, a partner at Atlas Venture who also invested in the company, wrote on his blog about how Avila (AH-vill-uh) paid off big-time for its early venture investors. The company raised just $51 million in venture capital its five-year history. The company is generating a 5x return on investment on the upfront payment from Celgene, which has potential to balloon to a 15x return if Avila hits its future milestones.

Booth offers some interesting background on the Avila story, and some lessons in four bullet points. “Avila has exhibited many of the hallmarks of a great biotech story today”: Specifically, he said those hallmarks are:

 Commitment to discovering and advancing real innovation

 Healthy focus on ‘equity capital efficiency’

 Dedication to creating strategic optionality for the company’s future

 And, most importantly, a fantastic team

Over on Twitter, Michael Gilman of Cambridge, MA-based Stromedix (@Michael_Gilman) recalled sitting in his living room more than five years ago with Avila co-founder Jus Singh, talking about his idea for the company. “The sweet thing about Avila is that it’s a triumph of data over dogma. People HATED covalent drugs. Avila changed their minds,” Gilman said on Twitter.

Avila Therapeutics CEO Katrine Bosley

You can read the Xconomy story on the deal by my colleague Arlene Weintraub. The one thing I’ll add is that I saw Avila CEO Katrine Bosley along with VP of corporate development Nagesh Mahanthappa and CFO Andrew Hirsch a couple weeks ago at the JP Morgan Healthcare Conference in San Francisco. Bosley talked a bit about how the company’s lead drug candidate, a Btk inhibitor, was being readied for mid-stage clinical trials against cancer later this year, and that it was thought to have potential against autoimmune diseases.

It was a quick meeting, and there wasn’t any hint that a deal this big was ready to be announced. But Hirsch tried to persuade me that maybe the IPO market for biotech isn’t as barren as some people think, which I took as a subtle hint that Avila might be sniffing around at that option. “I think there is an appetite from the investment community for high-quality stories,” Hirsch said.

And Mahanthappa optimistically noted that some big companies have been doing creative deals to support innovative biotechs. In particular, he singled out Celgene for its partnerships with Cambridge, MA-based Agios Pharmaceuticals and Acceleron Pharma. When I asked him about predictions for the year ahead, he predicted that creative deals like that would continue.

Comments | Reprints | Share:          

The unsolicited $5.7 billion offer that Roche made for Illumina will no doubt dominate San Diego’s biotech news for weeks to come. We have it and more.

—Switzerland’s Roche offered $5.7 billion, or $44.50 a share, for San Diego-based Illumina (NASDAQ: ILMN in a hostile bid disclosed yesterday. Roche’s bid to stake a claim in genetic diagnostics by acquiring the market-leading maker of DNA sequencing instruments would be the Swiss pharma giant’s biggest deal since its $46.8 billion buyout of Genentech almost two years ago. Roche is the world’s biggest maker of cancer drugs, which suggests its quest for Illumina represents a significant move to base cancer treatments on each patient’s genome.

—Venture capital investors sank $4.73 billion into 446 biotechs nationwide in 2011, according to the MoneyTree report from the National Venture Capital Association, PwC, and Thomson Reuters. But as Luke pointed out in his BioBeat column, there is an alarming drop in support for early stage life sciences startups. Only 153 biotech and medical device startups got their first round of financing in 2011, the lowest amount of seed investment activity in 15 years.

—At an Xconomy dinner discussion, former Amira Pharmaceuticals CEO Bob Baltera said insufficient access to capital is the biggest driver for decision-makers on both sides of biotech-pharma partnerships. So what are some other key factors? We asked some of San Diego’s life sciences leaders to explore the question in an “on the record” dinner discussion late last year.

—San Diego’s Sequenom (NASDAQ: SQNM) completed its secondary public offering, raising roughly $62 million in gross proceeds (before underwriting costs) in the sale of 14.95 million shares, including additional allotments granted to underwriters. Sequenom said it plans to use the net proceeds for … Next Page »

Comments | Reprints | Share: